NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired common stock of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE) between August 3, 2023 to December 26, 2025, inclusive. You are hereby notified that the class action lawsuit Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al. (Case No. 3:26-cv-01097) has been commenced in the United States District Court for the Northern District of California. To get more information go to:
https://zlk.com/pslra-1/ultragenyx-pharmaceutical-inc-lawsuit-submission-form-2
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of setrusumab’s potential and the true risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates or otherwise the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed.
On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not “achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.” The Company attributed the study failure to a “low fracture rate in the placebo group” of Orbit and a trend that fell shy of statistical significance in Cosmic.
Following this news, the price of Ultragenyx’s common stock declined dramatically. From a closing market price of $34.19 per share on December 26, 2025, Ultragenyx’s stock price fell to $19.72 per share on December 29, 2025, a decline of about 42.32% in the span of just a single day.
“Our firm is committed to ensuring that investors receive full compensation for losses caused by corporate misrepresentations,” said Joseph E. Levi, a partner at Levi & Korsinsky. “We encourage RARE shareholders to step forward before the April 6, 2026 deadline so we can pursue justice on their behalf.”
If you suffered a loss in RARE common stock, you have until April 6, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
